Protagonist Therapeutics Inc (PTGX)

02:21 AM

Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat

02:21 AM

12:23 PM

Is Protagonist Therapeutics Inc. stock entering bullish territoryWeekly Market Outlook & Accurate Intraday Trade Tips - newser.com

12:23 PM

Nov 02, 2025

Can Protagonist Therapeutics Inc. hit a new high this month2025 Earnings Impact & Short-Term High Return Ideas - newser.com

Nov 02, 2025

Nov 02, 2025

How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com

Nov 02, 2025

Nov 02, 2025

Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com

Nov 02, 2025

Nov 01, 2025

Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com

Nov 01, 2025

Nov 01, 2025

Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat

Nov 01, 2025

Nov 01, 2025

How Protagonist Therapeutics Inc. stock responds to policy changes2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com

Nov 01, 2025

Oct 31, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief

Oct 31, 2025

Oct 31, 2025

What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat

Oct 31, 2025

Oct 31, 2025

Protagonist Therapeutics Inc. stock chart pattern explained2025 Market Outlook & Weekly Top Gainers Alerts - newser.com

Oct 31, 2025

Oct 31, 2025

Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat

Oct 31, 2025

Oct 31, 2025

How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com

Oct 31, 2025

Oct 31, 2025

Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com

Oct 31, 2025

Oct 31, 2025

How Protagonist Therapeutics Inc. stock reacts to job market data2025 Market Outlook & Expert Curated Trade Setups - newser.com

Oct 31, 2025

Oct 30, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press

Oct 30, 2025

Oct 30, 2025

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Oct 30, 2025

Oct 29, 2025

How to track smart money flows in Protagonist Therapeutics Inc.2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com

Oct 29, 2025

Oct 29, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $86.00 at Wedbush - MarketBeat

Oct 29, 2025

Oct 29, 2025

Protagonist Therapeutics (PTGX) Price Target Increased by 10.06% to 78.69 - Nasdaq

Oct 29, 2025

Oct 29, 2025

BTIG Research Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat

Oct 29, 2025

Oct 29, 2025

State of New Jersey Common Pension Fund D Sells 12,711 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Oct 29, 2025

Oct 28, 2025

Wedbush Maintains Protagonist Therapeutics (PTGX) Outperform Recommendation - Nasdaq

Oct 28, 2025

Oct 28, 2025

Protagonist Therapeutics (PTGX): Truist Securities Raises Price Target to $88 | PTGX Stock News - GuruFocus

Oct 28, 2025

Oct 28, 2025

PTGX: Wedbush Raises Price Target to $86, Maintains Outperform R - GuruFocus

Oct 28, 2025

Oct 28, 2025

Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating - MarketScreener

Oct 28, 2025

Oct 28, 2025

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics - Benzinga

Oct 28, 2025

Oct 28, 2025

PTGX Maintains 'Buy' Rating with Price Target Steady at $82.00 | - GuruFocus

Oct 28, 2025